

## Letters to the Editor

### Codetection of *bla*<sub>OXA-23</sub>-Like Gene (*bla*<sub>OXA-133</sub>) and *bla*<sub>OXA-58</sub> in *Acinetobacter radioresistens*: Report from the SENTRY Antimicrobial Surveillance Program<sup>†</sup>

We read with great interest the report from Poirel et al. (7) describing *Acinetobacter radioresistens* as a source of *bla*<sub>OXA-23</sub>-like genes. During the 2006 SENTRY Antimicrobial Surveillance Program, the occurrence of acquired class D carbapenemases and metallo-β-lactamases in *Acinetobacter* spp. from the Asia-Pacific region was evaluated (4). In this study, one *A. radioresistens* strain (251-39C; identified by 16S rRNA gene sequencing) showing decreased susceptibility to penicillins and imipenem was observed (Manipal, India). However, since *bla*<sub>OXA-23</sub>-like genes from all *A. radioresistens* strains described by Poirel et al. (7) were silent and chromosome borne and did not confer a resistance phenotype, we were intrigued by the elevated MICs displayed by the isolate 251-39C. Therefore, further screening for class D carbapenemase (6, 10) detected *bla*<sub>OXA-58</sub> in addition to the intrinsic *bla*<sub>OXA-23</sub>-like gene.

Flanking sequences of both *bla*<sub>OXA</sub> genes were characterized by PCR using primers targeting IS*Aba1*, -2, or -3 or a degenerate primer approach (5, 9). The upstream region of the *bla*<sub>OXA-23</sub>-like gene showed the highest identity with a putative O-sialoglycoprotein endopeptidase gene detected in the *Acinetobacter baumannii* strain AYE (CU459141); no putative promoter was located in this region. Sequencing analysis of the *bla*<sub>OXA-23</sub>-like gene revealed a new gene, named *bla*<sub>OXA-133</sub>. The putative amino acid sequence displayed the most identity with OXA-102 (99.6%; one amino acid substitution difference [Leu-5 Phe]). Other close variants were OXA-103 (98.5%), OXA-23 (97.4%), OXA-73 (97.1%), OXA-27 and -49 (96.7%), and OXA-105 (96.3% [data not shown]) (7). A truncated ATPase located downstream of *bla*<sub>OXA-133</sub> was detected, consisting of the same genetic context as that reported previously (7). Sequencing confirmed the presence of *bla*<sub>OXA-58</sub> and IS*Aba3* upstream, thus providing a promoter region.

Plasmid analysis demonstrated nine plasmid bands (ca. 54, 35, 14, 5.6, 4.0, 3.0, 2.8, 2.5, and 2.4 kb) and a *bla*<sub>OXA-58</sub>-specific probe hybridized with the 54-, 35-, and 5.6-kb bands (5). It is worthwhile to mention that the 4.0-kb and smaller plasmid bands may represent different forms of at least two distinct plasmids. However, *bla*<sub>OXA-58</sub> was considered to be carried by three different plasmids, since they showed greater size differences. Further experiments should be performed to determine the exact number of plasmid DNAs carried by isolate 251-39C. Curing experiments were performed to investigate whether β-lactam MICs would decrease after removing *bla*<sub>OXA-58</sub>-carrying plasmids (3). Curing was confirmed by a negative PCR result for *bla*<sub>OXA-58</sub>. Index and cured strains were tested for susceptibility by the broth microdilution method (2) and Etest (AB BioDisk, Solna, Sweden). The cured *A. radioresistens* isolate became susceptible and showed MICs for penicillins and carbapenems between 128- and 16-fold and 4- to 32-fold lower than the index strain, respectively (Table 1).

In addition, we evaluated the transcriptional levels of *bla*<sub>OXA-133</sub> and *bla*<sub>OXA-58</sub> by using quantitative real-time PCR. RNA was extracted using the RNeasy mini kit (Qiagen GmbH, Hilden, Germany). Relative quantification of target gene expression (*bla*<sub>OXA-133</sub> and *bla*<sub>OXA-58</sub>) was performed in tripli-

TABLE 1. MICs for *A. radioresistens* index and cured strains tested against several antimicrobial agents

Antimicrobial agent	MIC (μg/ml)	
	Index <i>A. radioresistens</i> 251-39C strain	Cured <i>A. radioresistens</i> strain
Amoxicillin-clavulanate	32	2
Ampicillin-sulbactam	1	1
Piperacillin-tazobactam	64	1
Ticarcillin-clavulanate	>256	4
Aztreonam	8	8
Cefoxitin	8	8
Ceftazidime	0.5	0.5
Ceftriaxone	4	2
Cefepime	0.5	0.25
Ertapenem	4	1
Imipenem	8	0.25
Meropenem	1	0.25
Ciprofloxacin	0.06	0.12
Amikacin	0.5	0.5
Tobramycin	2	2
Tetracycline	≤2	≤2
Polymyxin B	≤0.5	≤0.5
Trimethoprim-sulfamethoxazole	≤0.5	≤0.5

cate by normalization to an endogenous reference (16S rRNA). Quantitative real-time PCR demonstrated that *bla*<sub>OXA-133</sub> was transcribed at very low levels (mean threshold cycle = 34.74), ca. 1,500-fold lower than those for *bla*<sub>OXA-58</sub> (mean threshold cycle = 24.00). Although the index strain harbored the chromosomal *bla*<sub>OXA-133</sub>, the loss of β-lactam resistance displayed by the cured strain suggests OXA-58 as the main β-lactam resistance mechanism (8), possibly enhanced by multiple gene copies and increased production of enzyme (1). Detection of *bla*<sub>OXA-58</sub> in the index strain, highly disseminated in *A. baumannii* (4), indicates the occurrence of DNA exchange between these two species (7). Furthermore, our findings emphasize the ability of *bla*<sub>OXA-58</sub> mobilization.

**Nucleotide sequence accession number.** The nucleotide sequences of the *bla*<sub>OXA-133</sub>-carrying *A. radioresistens* clinical isolate described in this paper have been submitted to the EMBL/GenBank/DNA Data Bank of Japan sequence databases and assigned the accession number EU571228.

#### REFERENCES

- Bertini, A., L. Poirel, S. Bernabeu, D. Fortini, L. Villa, P. Nordmann, and A. Carattoli. 2007. Multicopy *bla*<sub>OXA-58</sub> gene as a source of high-level resistance to carbapenems in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **51**:2324–2328.
- CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A8. CLSI, Wayne, PA.
- Hirota, Y. 1960. The effect of acridine dyes on mating type factors in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **46**:57–64.
- Mendes, R. E., J. M. Bell, J. D. Turnidge, M. Castanheira, and R. N. Jones.

2008. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among *Acinetobacter* spp. in Asia-Pacific nations: report from the SENTRY Antimicrobial Surveillance Program. *J. Antimicrob. Chemother.* **63**:55–59.
5. **Mendes, R. E., M. Castanheira, M. A. Toleman, H. S. Sader, R. N. Jones, and T. R. Walsh.** 2007. Characterization of an integron carrying *bla*<sub>IMP-1</sub> and a new aminoglycoside resistance gene, *aac*(6′)-3I, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. *Antimicrob. Agents Chemother.* **51**:2611–2614.
6. **Mendes, R. E., K. A. Kiyota, J. Monteiro, M. Castanheira, S. S. Andrade, A. C. Gales, A. C. Pignatari, and S. Tufik.** 2007. Rapid detection and identification of metallo-β-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. *J. Clin. Microbiol.* **45**:544–547.
7. **Poirel, L., S. Figueiredo, V. Cattoir, A. Carattoli, and P. Nordmann.** 2008. *Acinetobacter radioresistens* as a silent source of carbapenem resistance for *Acinetobacter* spp. *Antimicrob. Agents Chemother.* **52**:1252–1256.
8. **Poirel, L., S. Marque, C. Heritier, C. Segonds, G. Chabanon, and P. Nordmann.** 2005. OXA-58, a novel class D β-lactamase involved in resistance to carbapenems in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **49**:202–208.
9. **Poirel, L., and P. Nordmann.** 2006. Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene *bla*<sub>OXA-58</sub> in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **50**:1442–1448.
10. **Woodford, N., M. J. Ellington, J. M. Coelho, J. F. Turton, M. E. Ward, S. Brown, S. G. Amyes, and D. M. Livermore.** 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. *Int. J. Antimicrob. Agents* **27**:351–353.

**Rodrigo E. Mendes\***

*JMI Laboratories  
345 Beaver Creek Centre, Suite A  
North Liberty, Iowa 52317*

**Jan M. Bell**

**John D. Turnidge**  
*Women's and Children's Hospital  
Adelaide, Australia*

**Mariana Castanheira  
Lalitagauri M. Deshpande  
Ronald N. Jones**  
*JMI Laboratories  
North Liberty, Iowa*

\*Phone: (319) 665–3370

Fax: (319) 655–3371

E-mail: rodrigo-mendes@jmilabs.com

<sup>†</sup> Published ahead of print on 17 November 2008.